...
首页> 外文期刊>Renal failure. >Lysophosphatidic acid and lovastatin might protect kidney in renal I/R injury by downregulating MCP-1 in rat
【24h】

Lysophosphatidic acid and lovastatin might protect kidney in renal I/R injury by downregulating MCP-1 in rat

机译:溶血磷脂酸和洛伐他汀可能通过下调大鼠MCP-1来保护肾脏I / R损伤中的肾脏

获取原文
获取原文并翻译 | 示例

摘要

Renal ischemia/reperfusion (I/R) injury is a major cause of renal failure. The aim of our study is to explore the role of lysophosphatidic acid (LPA) and lovastatin on renal I/R injury and its mechanism in the rat. Male Wistar rats were randomly divided into sham-operated group; renal I/R for 0 h, 4 h, 12 h, and 24 h groups; LPA treatment group; and lovastatin treatment group (n = 10). Rats were killed to determine the level of monocyte chemotactic protein-1 (MCP-1) in renal tissue, renal function [serum creatinine (Cr) and blood urea nitrogen (BUN)], and renal histomorphology to evaluate the effectiveness of LPA and lovastatin. Normal renal tissue had a low level of MCP-1. The level of MCP-1 began to rise at 0 h after reperfusion, reached peak value at 4 h, and then gradually fell off. Compared with sham-operated group, MCP-1 was increased in all renal I/R injury groups (p < 0.01). With the extension of reperfusion, Cr and BUN were significantly increased (p < 0.01). There were damages in kidney tubules, renal interstitium, and kidney glomerulus in renal I/R injury groups. Paller's score was significantly increased in all renal I/R injury groups compared with sham-operated group (p < 0.01). LPA and lovastatin reduced the level of MCP-1, Cr, BUN, and damages of renal histomorphology (p < 0.01). The level of MCP-1 in renal tissue dynamically increases in renal I/R injury, indicating that MCP-1 is involved in renal I/R injury. LPA and lovastatin might protect renal function by downregulating MCP-1 in renal I/R injury.
机译:肾缺血/再灌注(I / R)损伤是肾衰竭的主要原因。我们的研究目的是探讨溶血磷脂酸(LPA)和洛伐他汀在大鼠肾脏I / R损伤中的作用及其机制。将雄性Wistar大鼠随机分为假手术组。 0 h,4 h,12 h和24 h组的肾脏I / R; LPA治疗组;洛伐他汀治疗组(n = 10)。处死大鼠以确定肾脏组织中单核细胞趋化蛋白-1(MCP-1)的水平,肾功能[血清肌酐(Cr)和血尿素氮(BUN)],并通过肾脏组织形态学评估LPA和洛伐他汀的有效性。正常肾脏组织的MCP-1水平较低。 MCP-1的水平在再灌注后0 h开始上升,在4 h达到峰值,然后逐渐下降。与假手术组相比,所有肾脏I / R损伤组的MCP-1均升高(p <0.01)。随着再灌注的延长,Cr和BUN显着增加(p <0.01)。肾脏I / R损伤组的肾小管,肾间质和肾小球均受损。与假手术组相比,所有肾脏I / R损伤组的Paller评分均显着提高(p <0.01)。 LPA和洛伐他汀降低了MCP-1,Cr,BUN的水平,并降低了肾脏的组织形态(p <0.01)。肾I / R损伤中肾组织中MCP-1的含量动态增加,表明MCP-1参与了肾I / R损伤。 LPA和洛伐他汀可能通过下调ICP肾损伤中的MCP-1来保护肾功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号